NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 03 04:00PM ET
1.19
Dollar change
-0.05
Percentage change
-4.03
%
Index- P/E- EPS (ttm)-20.65 Insider Own28.11% Shs Outstand4.38M Perf Week15.53%
Market Cap5.21M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float3.15M Perf Month-7.75%
Enterprise Value-9.02M PEG- EPS next Q- Inst Own2.62% Short Float0.12% Perf Quarter-17.36%
Income-10.71M P/S- EPS this Y- Inst Trans-55.73% Short Ratio0.00 Perf Half Y-87.20%
Sales0.00M P/B1.11 EPS next Y- ROA-72.63% Short Interest0.00M Perf YTD-86.55%
Book/sh1.07 P/C0.37 EPS next 5Y- ROE-1191.31% 52W High27.25 -95.63% Perf Year-95.09%
Cash/sh3.25 P/FCF- EPS past 3/5Y64.27% 51.52% ROIC-296.87% 52W Low0.89 33.32% Perf 3Y-99.74%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility35.55% 12.89% Perf 5Y-99.95%
Dividend TTM- EV/Sales- EPS Y/Y TTM91.07% Oper. Margin- ATR (14)0.20 Perf 10Y-
Dividend Ex-Date- Quick Ratio1.34 Sales Y/Y TTM- Profit Margin- RSI (14)49.59 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio1.34 EPS Q/Q99.77% SMA200.66% Beta2.15 Target Price500.00
Payout- Debt/Eq0.00 Sales Q/Q- SMA50-0.24% Rel Volume0.69 Prev Close1.24
Employees6 LT Debt/Eq0.00 Earnings- SMA200-79.19% Avg Volume924.49K Price1.19
IPOAug 22, 2017 Option/ShortNo / Yes EPS/Sales Surpr.-150.00% - Trades Volume638,446 Change-4.03%
Date Action Analyst Rating Change Price Target Change
May-18-21Initiated BTIG Research Buy $11
Oct-02-20Initiated B. Riley FBR Buy $9
Nov-20-19Initiated Cantor Fitzgerald Overweight $7
Aug-13-19Initiated H.C. Wainwright Buy $7
Jun-21-19Initiated Cantor Fitzgerald Overweight $7
Dec-21-17Initiated Oppenheimer Outperform $18
Mar-05-25 04:15PM
Feb-27-25 04:05PM
Feb-11-25 04:10PM
Feb-10-25 08:00AM
Feb-06-25 07:00AM
08:00AM Loading…
Jan-14-25 08:00AM
Nov-12-24 08:30AM
Nov-08-24 06:36AM
Nov-07-24 08:30AM
Oct-26-24 05:20PM
Oct-24-24 02:10PM
Jun-28-24 08:00AM
Jun-21-24 04:01PM
Jun-20-24 05:26PM
08:00AM
07:28AM Loading…
07:28AM
Jun-18-24 10:22AM
07:37AM
07:30AM
Jun-17-24 01:28PM
01:03PM
12:07PM
08:30AM
May-22-24 08:04AM
07:23AM
May-16-24 10:53AM
May-02-24 04:01PM
Apr-30-24 06:03AM
Apr-29-24 08:00PM
Mar-28-24 04:05PM
09:00AM Loading…
09:00AM
Mar-11-24 04:05PM
Mar-07-24 07:30AM
Jan-11-24 08:30AM
Dec-11-23 08:30AM
Nov-14-23 04:05PM
Nov-02-23 09:28AM
Oct-30-23 02:15PM
Oct-26-23 12:30PM
09:00AM
Sep-07-23 08:15AM
Aug-16-23 08:00AM
Aug-14-23 04:05PM
04:01PM
Aug-03-23 08:00AM
Jul-31-23 08:30AM
Jul-06-23 08:00AM
Jun-15-23 04:01PM
Jun-13-23 01:49PM
Jun-12-23 09:55AM
08:00AM
May-26-23 09:55AM
May-18-23 08:03AM
May-15-23 04:01PM
May-12-23 04:05PM
May-11-23 04:03PM
Apr-03-23 12:15PM
Mar-30-23 04:10PM
Mar-29-23 04:15PM
Mar-28-23 08:30AM
Jan-17-23 08:15AM
Dec-19-22 08:30AM
Nov-14-22 04:05PM
Oct-27-22 08:00AM
Oct-06-22 08:30AM
Sep-08-22 08:00AM
Sep-02-22 09:55AM
Aug-11-22 04:05PM
Jul-27-22 08:00AM
Jul-17-22 08:21AM
Jun-22-22 08:00AM
Jun-13-22 08:00AM
May-19-22 03:23PM
08:45AM
May-12-22 04:05PM
10:38AM
May-03-22 08:00AM
Apr-25-22 08:00AM
Apr-21-22 08:30AM
Apr-13-22 10:00AM
Apr-04-22 08:00AM
Apr-01-22 08:30AM
Mar-23-22 04:05PM
Mar-10-22 08:30AM
Mar-09-22 08:00AM
Mar-08-22 09:00AM
Feb-15-22 07:30AM
Feb-08-22 08:30AM
Feb-07-22 09:11AM
Jan-25-22 07:10AM
Jan-24-22 05:00PM
Jan-07-22 02:05PM
Jan-05-22 08:30AM
Dec-16-21 08:30AM
Dec-13-21 09:00AM
Dec-09-21 08:30AM
Dec-06-21 07:30AM
Nov-12-21 08:05AM
Nov-10-21 08:00AM
Nov-09-21 09:02AM
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the translation of medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline includes CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors, and gene therapies for rare genetic disorders. The company was founded on March 13, 2015 and is headquartered in Waltham, MA.